证券代码：002399 证券简称：海普瑞 公告编号：2025-002 1、业绩预告期间：2024年01月01日-2024年12月31日 2、预计的经营业绩：□亏损 √扭亏为盈 □同向上升 □同向下降 | 项 目 | 本报告期 | | | 上年同期 | | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股 东的净利润 | 盈利：58,900 | 万元–71,100 | 万元 | 亏损：78,326 | 万元 | | 扣除非经常性损益 后的净利润 | 盈利：21,400 | 万元–31,200 | 万元 | 亏损：77,984 | 万元 | | 基本每股收益 | 盈利：0.4014 | 元/股–0.4846 | 元/股 | 亏损：0.5338 | 元/股 | 二、与会计师事务所沟通情况 本次业绩预告相关数据未经会计师事务所审计。但公司已就业绩预告与会计 师事务所进行了预沟通，双方对本次业绩预告不存在重大分歧。 三、业绩变动原因说明 深圳市海普瑞药业集团股份有限公司 2024年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性 ...

证券时报e公司讯，海普瑞(002399)1月2日晚间公告，公司于2024年12月31日与浙江永太药业有限公司 （简称"永太药业"）签订分销协议，永太药业授予海普瑞在美国全境商业化加巴喷丁胶囊Gabapentin的 许可。 加巴喷丁是一种常用的抗癫痫药物，被广泛用于治疗神经痛和其他疼痛性疾病，可能的作用机制有影响 γ-氨基丁酸的合成和释放，与电压门控钙通道的亚单位结合以及调节谷氨酸能神经元。 ...

证券代码：002399 证券简称：海普瑞 公告编号：2024-041 深圳市海普瑞药业集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市海普瑞药业集团股份有限公司（以下简称"公司"）于2024年12月6 日召开的第六届董事会第十三次会议审议通过了《关于延长第二期员工持股计划 存续期的议案》及《关于延长第三期员工持股计划存续期的议案》，同意将公司 第二期员工持股计划存续期延长12个月至2025年12月11日止，将公司第三期员工 持股计划存续期延长12个月至2025年12月27日止。现将相关事项公告如下： 一、员工持股计划的基本情况 （一）第二期员工持股计划 公司于2016年11月25日召开第三届董事会第二十九次会议、2016年12月12 日召开2016年第三次临时股东大会，审议通过了《关于公司第二期员工持股计划 （草案）及摘要的议案》等相关议案。公司第二期员工持股计划存续期为员工持 股计划经股东大会审议通过之日起36个月，即2016年12月12日至2019年12月11 日。 2017年3月9日，第二期员工持股计划完成股票购买，共计购买公司股 ...

证券代码：002399 证券简称：海普瑞 公告编号：2024-040 深圳市海普瑞药业集团股份有限公司 第六届董事会第十三次会议决议公告 与会董事认真审议并通过了以下议案： 1、《关于延长第二期员工持股计划存续期的议案》 表决结果：7票同意、0票弃权、0票反对。 具体内容详见公司同日披露于《证券时报》《中国证券报》《上海证券报》 《证券日报》和巨潮资讯网www.cninfo.com.cn的《关于延长员工持股计划存续 期的公告》。 2、《关于延长第三期员工持股计划存续期的议案》 表决结果：7票同意、0票弃权、0票反对。 具体内容详见公司同日披露于《证券时报》《中国证券报》《上海证券报》 《证券日报》和巨潮资讯网www.cninfo.com.cn的《关于延长员工持股计划存续 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市海普瑞药业集团股份有限公司（以下简称"公司"）第六届董事会第 十三次会议（以下简称"会议"）通知及议案于2024年12月3日以电子邮件的形 式发出，会议于2024年12月6日下午14:00在深圳市南山区松坪山朗山路2 ...

Financial Performance - The company's revenue for Q3 2024 was CNY 1,231,523,140.11, representing a decrease of 8.80% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was CNY 116,430,360.57, an increase of 487.43% year-over-year[2] - The net profit after deducting non-recurring gains and losses reached CNY 99,358,854.26, showing a significant increase of 1,631.43% compared to the previous year[2] - Basic and diluted earnings per share for Q3 2024 were both CNY 0.0794, reflecting an increase of 488.15% year-over-year[2] - The net profit for the third quarter of 2024 reached CNY 779,059,287.68, representing a 449.08% increase compared to the same period last year[7] - Operating profit increased to CNY 903,477,746.40, up 405.25% year-on-year, primarily due to reduced expenses and increased investment income[7] - Total profit amounted to CNY 887,202,773.78, reflecting a 389.69% increase year-on-year[7] - The company reported a total comprehensive income of CNY 713,437,124.04 for the quarter, compared to CNY 242,978,158.09 in the same period last year, marking an increase of about 194%[15] Cash Flow and Investments - The company's cash flow from operating activities for the year-to-date period was CNY 428,828,218.59, an increase of 402.43% compared to the same period last year[2] - The net cash flow from operating activities was CNY 1,792,139,231.56, a significant improvement of 865.91% compared to a negative cash flow of CNY -233,988,970.92 in the previous year[8] - Investment activities generated a net cash flow of CNY -226,221,859.93, a decline of 117.24% compared to the previous year[8] - The company reported a net cash outflow from investing activities of CNY -226,221,859.93, a significant decline from a net inflow of CNY 1,312,338,280.10 in the same period last year[16] Assets and Liabilities - Total assets at the end of Q3 2024 were CNY 18,121,417,326.69, a decrease of 5.63% from the end of the previous year[2] - The company's cash and cash equivalents increased to CNY 2,242,888,528.02 from CNY 1,851,642,224.58, representing a growth of about 21.1%[11] - Total assets decreased to CNY 18,121,417,326.69 from CNY 19,203,415,131.24, reflecting a decline of approximately 5.6%[12] - The total liabilities reduced to CNY 5,906,888,588.09 from CNY 7,215,037,414.42, a decrease of around 18.1%[12] - The company reported a decrease in total current liabilities to CNY 4,341,291,665.37 from CNY 4,986,180,302.15, a reduction of approximately 13.0%[12] - The total owner's equity increased to CNY 12,214,528,738.60 from CNY 11,988,377,716.82, reflecting a growth of about 1.9%[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,499[9] - The largest shareholder, Shenzhen Lerun Technology Co., Ltd., holds 32.31% of the shares, totaling 474,029,899 shares[9] Expenses and Income - Sales expenses for the year-to-date period decreased by 30.26% to CNY 280,983,594.46, attributed to reduced marketing expenses[6] - The company experienced a 53.92% decrease in other income, totaling CNY 9,392,939.82, mainly due to reduced government subsidies[6] - The company’s total tax expenses increased by 175.25% to CNY 108,143,486.10, driven by the rise in total profit[7] - The company reported a decrease in credit impairment losses by 455.16%, amounting to CNY 11,001,914.40[7] - The company experienced a significant increase in asset disposal gains, which rose by 212.88% to CNY 620,158.53[7] Research and Development - Research and development expenses for the period were CNY 129,976,981.05, down from CNY 152,223,825.20, a reduction of about 14.6%[14] Revenue from Sales - Total revenue from sales of goods and services was CNY 4,299,443,691.71, down from CNY 4,603,550,675.54 in Q3 2023, reflecting a decrease of approximately 6.6%[16]

| | 深圳市天道医药有 | 全资孙公司 | 应收账款 | 89,305.76 | 118,657.18 | 155,345.22 | 52,617.72 | 往来款 | 经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 限公司 | | | | | | | | | | | 海普瑞（香港）有限 公司 | 全资子公司 | 应收账款 | - | 1,797.16 | 1,797.16 | - | 往来款 | 经营性往来 | | | Hepalink USA INC. | 全资子公司 | 应收账款 | 8.69 | 0.07 | 0.01 | 8.75 | 往来款 | 经营性往来 | | | Techdow Pharma Italy | 全资子公司 | 应收账款 | 12.40 | 0.09 | 0.02 | 12.47 | 往来款 | 经营性往来 | | 其他关联方及其附 属企业 | Resver logix Corp. | 联营公司 | 其他应收款 | 4,537.10 | 28.25 | | 4,565.35 | ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2024, representing a year-on-year increase of 15%[7]. - The net profit attributable to shareholders was RMB 300 million, up 20% compared to the same period last year[7]. - The company's operating revenue for the reporting period was ¥2,837,400,906.87, an increase of 4.59% compared to ¥2,712,899,392.07 in the same period last year[12]. - Net profit attributable to shareholders was ¥663,683,451.42, representing a significant increase of 438.05% from ¥123,349,841.18 in the previous year[12]. - The net profit after deducting non-recurring gains and losses was ¥329,469,364.33, up 313.85% from ¥79,611,755.54 year-on-year[12]. - The company achieved a net cash inflow from operating activities of RMB 1.295 billion, a year-on-year increase of 338.57%[33]. - The company reported a significant increase in financial assets measured at fair value, with changes recognized in other comprehensive income[182]. Market Expansion and Product Development - The company plans to launch three new products in the second half of 2024, focusing on innovative therapies for rare diseases[7]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[7]. - User data showed an increase in active users by 25%, reaching 5 million by the end of June 2024[7]. - The company expects a revenue growth forecast of 10% for the second half of 2024, driven by new product launches and market expansion strategies[178]. - New product development includes the launch of a groundbreaking drug expected to enter the market in Q4 2024, projected to generate 300 million RMB in sales[178]. - The company is actively exploring new markets in Asia and South America to supplement its non-European and American overseas market[35]. Research and Development - The R&D expenditure for the first half of 2024 was RMB 150 million, accounting for 12.5% of total revenue[7]. - The company has invested 150 million RMB in R&D for innovative technologies aimed at improving production efficiency[178]. - Research and development investment was RMB 81.79 million, a decrease of 16.60% compared to the previous year[42]. - The company focuses on innovative drug candidates for treating life-threatening diseases, leveraging over 20 years of research experience in polysaccharide chemistry[27]. Financial Guidance and Strategy - The company has set a revenue guidance of RMB 2.5 billion for the full year 2024, indicating a growth target of 12%[7]. - The financial outlook remains positive, with an anticipated EBITDA margin improvement of 5% by the end of 2024[178]. - The company plans to implement cost-cutting measures that could save approximately 50 million RMB annually[178]. - The company has adjusted its investment strategy, resulting in an investment income of RMB 272 million from the reduction of equity in a joint venture[33]. Risk Management - The company has identified potential risks including regulatory changes and market competition, with strategies in place to mitigate these risks[2]. - The company faces significant risks related to product quality, market competition, and raw material price fluctuations, which could adversely affect revenue and profitability[66][68]. - The company is actively enhancing its quality control measures and employee training to mitigate product quality risks[65]. - The company is focusing on optimizing its supply chain and cost management to address the impact of raw material price volatility on its operations[68]. Environmental Compliance - The company strictly adheres to various environmental protection laws and standards during its operations, including the Air Pollution Prevention and Control Law and the Water Pollution Prevention and Control Law[80]. - The company has implemented a comprehensive environmental monitoring system, with real-time data uploaded to regulatory platforms[91]. - The company reported a total nitrogen oxide emissions of 20.42 tons per year, with no exceedance of standards[83]. - The company achieved a non-methane total hydrocarbon emission of 1.168 tons per year, remaining compliant with environmental regulations[84]. Shareholder Information - A total of 240 employees from the company and its subsidiaries hold 15,118,035 shares, representing 1.03% of the total share capital[77]. - The largest shareholder, Shenzhen Le Ren Technology Co., Ltd., holds 32.31% of shares, totaling 474,029,899[121]. - The company has not reported any changes in the controlling shareholder or actual controller during the reporting period[125]. Financial Position - Total assets at the end of the reporting period were ¥18,573,510,350.97, a decrease of 3.28% from ¥19,203,415,131.24 at the end of the previous year[12]. - The company's total liabilities decreased to CNY 3,977,865,906.81 in the first half of 2024 from CNY 4,973,733,165.30 in the first half of 2023, a reduction of approximately 20%[143]. - The total equity of the company increased to CNY 8,961,083,565.77 in the first half of 2024, up from CNY 8,882,940,836.16 in the same period of 2023[143]. Compliance and Governance - The company received a corrective action order from the China Securities Regulatory Commission due to internal control deficiencies[96]. - The company has developed a rectification plan in response to regulatory findings, which was approved by the board of directors[97]. - The company has maintained compliance with environmental protection tax obligations and has purchased environmental liability insurance[89].

Research and Development Center 肝素原料药制剂一体化龙头，业绩有望企稳修复 [Table_CoverStock] —海普瑞(002399)公司首次覆盖报告 [Table_ReportDate] 2024 年 08 月 09 日 [Table_CoverAuthor] 唐爱金 医药行业首席分析 师 S1500523080002 tangaijin@cindasc.com | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - The company expects a net profit attributable to shareholders of between 642.28 million and 734.82 million yuan for the first half of 2024, representing a year-on-year increase of 420.70% to 495.72% compared to 123.35 million yuan in the same period last year[8]. - The net profit after deducting non-recurring gains and losses is projected to be between 308.07 million and 400.61 million yuan, reflecting a year-on-year growth of 286.96% to 403.20% from 79.61 million yuan last year[8]. - The basic earnings per share is expected to be between 0.4377 yuan and 0.5008 yuan, compared to 0.0841 yuan per share in the same period last year[8]. Market and Industry Trends - The heparin industry chain's operating environment has improved, with signs of market demand recovery, leading to a positive development trend in the heparin formulation business[9]. - The global demand for heparin API has rebounded, with a significant increase in export volume from China compared to the same period last year, despite a notable decline in export prices due to upstream raw material price drops[10]. Investment Strategy - The company has disposed of part of its equity in HighTide Therapeutics, Inc., which is expected to generate over 250 million yuan in investment income, to be included in non-recurring gains and losses[10]. - The company continues to optimize its external investment strategy to maximize shareholder interests and has made significant progress in its investment portfolio[10]. Business Operations - The CDMO business has continued its recovery, with the company strengthening strategic partnerships with existing clients and exploring new customer groups[4]. - The gross profit margin of formulation products has improved compared to the same period last year, excluding the impact of centralized procurement pricing in the Chinese market[3]. - The company emphasizes maintaining a good pricing system and cost control efficiency in its heparin API business, achieving better average prices than the overall export average from China[10].

北京中银（深圳）律师事务所 关于深圳市海普瑞药业集团股份有限公司 2023 年年度股东大会的 法律意见书 地址：深圳市福田区益田路 6003 号荣超商务中心 A 座 5、6 层 电话：（86-755）82531588 传真：（86-755）82531555 邮编：518026 北京中银（深圳）律师事务所 法律意见书 北京中银（深圳）律师事务所 关于深圳市海普瑞药业集团股份有限公司 2023 年年度股东大会的 法律意见书 致：深圳市海普瑞药业集团股份有限公司 北京中银（深圳）律师事务所（以下简称"本所"）接受深圳市海普瑞药业集 团股份有限公司（以下简称"公司"）委托，就公司召开 2023 年年度股东大会（以 下简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简 称《公司法》）《上市公司股东大会规则》等法律、法规、规章和其他规范性文 件以及《深圳市海普瑞药业集团股份有限公司章程》（以下简称《公司章程》） 的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤 ...